Merus Acquisition Officially Clears Path: Genmab's $97 Bid Secured 94.2% Support

DAOdreamer · 2025-12-26T05:41:23+00:00

Genmab successfully completed its acquisition of Merus, with 94.2% shareholder approval. The deal enhances Genmab's portfolio with Merus's petosemtamab, projected to generate over $1 billion annually by 2029. An extended offer period allows remaining shareholders to sell their shares.

DAOdreamer

2025-12-26 05:41:23

Abstract generation in progress

Genmab’s bid to fully acquire Merus has now crossed the finish line. The Danish biotech firm’s holding subsidiary confirmed that all conditions for its $97-per-share cash offer have been satisfied, with overwhelming shareholder backing—94.2% of outstanding Merus shares were tendered by the December 11 deadline, totaling 71,463,077 shares.

What This Deal Means for Genmab’s Future

The acquisition aligns with Genmab’s strategic shift toward operating as a fully integrated entity. More importantly, it brings Merus’ flagship drug petosemtamab into Genmab’s portfolio, positioning the company to expand its pipeline with a high-potential asset. According to management guidance, petosemtamab is expected to hit the market in 2027, with revenue projections reaching at least $1 billion annually by 2029—a significant milestone that could reshape the company’s growth trajectory.

The Extended Offer Window

Shareholders still have a chance to participate. A ten-business-day subsequent offering period launched on December 12 and runs through December 29 at 5:00 p.m. EST. During this window, Genmab will continue purchasing remaining Merus shares at the identical $97-per-share rate, with immediate settlement and prompt payment processing.

Any Merus shareholders who don’t tender during this extended period will see their remaining shares acquired through follow-on procedures already disclosed by the company, with compensation arriving after those steps conclude.

Market Reaction Reflects Deal Confidence

Investor sentiment appeared positive following the announcement. Genmab’s stock closed regular trading on December 12 at $32.30, representing a gain of $1.06 or 3.39% for the session. After-hours trading showed additional momentum, with the price climbing to $33.30 by 11:00 PM EST, marking another $1 or 3.10% increase—suggesting the market views this strategic consolidation favorably.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.